One-step high-efficiency CRISPR/Cas9-mediated genome editing in Streptomyces

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 4, 2015, Pages 231-243

  Huang, He ^a,b   Zheng, Guosong ^a   Jiang, Weihong ^a   Hu, Haifeng ^b   Lu, Yinhua ^a  

^a INSTITUTE OF PLANT PHYSIOLOGY AND ECOLOGY   (China)

^b SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

Author keywords

CRISPRs (clustered regularly interspaced short palindromic repeats); genome editing; Streptomyces

Indexed keywords

ACTINOMYCES; ESCHERICHIA COLI; LACTOBACILLUS REUTERI; STREPTOCOCCUS; STREPTOMYCES; STREPTOMYCES COELICOLOR;

BACTERIAL PROTEIN;

BACTERIAL GENOME; BIOLOGICAL MODEL; CRISPR CAS SYSTEM; GENE DELETION; GENETIC ENGINEERING; GENETICS; GENOTYPE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PLASMID; POINT MUTATION; PROCEDURES; REPRODUCIBILITY; STREPTOMYCES COELICOLOR;

BACTERIAL PROTEINS; BASE SEQUENCE; CRISPR-CAS SYSTEMS; GENE DELETION; GENETIC ENGINEERING; GENOME, BACTERIAL; GENOTYPE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; PLASMIDS; POINT MUTATION; REPRODUCIBILITY OF RESULTS; STREPTOMYCES COELICOLOR;

EID: 84926466507     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmv007     Document Type: Article

References (60)

1. Baltz RH. Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 2008, 8: 557-563.
2. Demain AL. Pharmaceutically active secondary metabolites of microorganisms. Appl Microbiol Biotechnol 1999, 52: 455-463.
3. Fostel JM, Lartey PA. Emerging novel antifungal agents. Drug Discov Today 2000, 5: 25-32.
4. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, Aoki H, et al. Discovery of FK-506, a novel immunosuppressant isolated from streptomyces-tsukubaensis. Transplant Proc 1987, 19: 4-8.
5. Nett M, Ikeda H, Moore BS. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat Prod Rep 2009, 26: 1362-1384.
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70: 461-477.
7. Olano C, Mendez C, Salas JA. Antitumor compounds from marine actinomycetes. Mar Drugs 2009, 7: 210-248.
8. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, et al. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc 2006, 128: 11916-11920.
9. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441: 358-361.
10. Watve MG, Tickoo R, Jog MM, Bhole BD. How many antibiotics are produced by the genus Streptomyces? Arch Microbiol 2001, 176: 386-390.
11. Berdy J. Bioactive microbial metabolites-a personal view. J Antibiot 2005, 58: 1-26.
12. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75: 311-335.
13. Hair PI, Keam SJ. Daptomycin-a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007, 67: 1483-1512.
14. Jeya M, Moon HJ, Lee KM, Kim IW, Lee JK. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Curr Pharm Biotechnol 2011, 12: 1194-1204.
15. Scott D, Chen J-M, Bae Y, Rohr J. Semi-synthetic mithramycin SA derivatives with improved anticancer activity. Chem Biol Drug Des 2013, 81: 615-624.
16. Pettit RK. Small-molecule elicitation of microbial secondary metabolites. Microb Biotechnol 2011, 4: 471-478.
17. Genilloud O, Gonzalez I, Salazar O, Martin J, Ruben Tormo J, Vicente F. Current approaches to exploit actinomycetes as a source of novel natural products. J Ind Microbiol Biotechnol 2011, 38: 375-389.
18. McAlpine JB, Bachmann BO, Piraee M, Tremblay S, Alarco AM, Zazopoulos E, Farnet CM. Microbial Genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. J Nat Prod 2005, 68: 493-496.
19. Udwary DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, Jensen PR, et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci USA 2007, 104: 10376-10381.
20. Winter JM, Behnken S, Hertweck C. Genomics-inspired discovery of natural products. Curr Opin Chem Biol 2011, 15: 22-31.
21. Zakeri B, Lu TK. Synthetic biology of antimicrobial discovery. ACS Synth Biol 2013, 2: 358-372.
22. Wright G. Perspective: synthetic biology revives antibiotics. Nature 2014, 509: S13-S13.
23. Tyo KEJ, Kocharin K, Nielsen J. Toward design-based engineering of industrial microbes. Curr Opin Microbiol 2010, 13: 255-262.
24. Leprince A, van Passel MWJ, Dos Santos VAPM. Streamlining genomes: toward the generation of simplified and stabilized microbial systems. Curr Opin Biotechnol 2012, 23: 651-658.
25. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000, 97: 6640-6645.
26. Gust B, Challis GL, Fowler K, Kieser T, Chater KF. PCR-targeted Streptomyces gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin. Proc Natl Acad Sci USA 2003, 100: 1541-1546.
27. Komatsua M, Uchiyama T, Omura S, Cane DE, Ikeda H. Genomeminimized Streptomyces host for the heterologous expression of secondary metabolism. Proc Natl Acad Sci USA 2010, 107: 2646-2651.
28. Wirth D, Gama-Norton L, Riemer P, Sandhu U, Schucht R, Hauser H. Road to precision: recombinase-based targeting technologies for genome engineering. Curr Opin Biotechnol 2007, 18: 411-419.
29. Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science 2010, 327: 167-170.
30. Garneau JE, Dupuis M-E, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 2010, 468: 67-71.
31. Hale CR, Zhao P, Olson S, Duff MO, Graveley BR, Wells L, Terns RM, et al. RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell 2009, 139: 945-956.
32. Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, Dickman MJ, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 2008, 321: 960-964.
33. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315: 1709-1712.
34. Bolotin A, Ouinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 2005, 151: 2551-2561.
35. Cho SW, Kim S, Kim JM, Kim J-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013, 31: 230-232.
36. Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, Wildonger J, et al. Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics 2013, 194: 1029-1035.
37. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson JA. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA 2013, 110: 15644-15649.
38. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife 2013, 2: e00471.
39. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013, 153: 910-918.
40. Frichot E, Mathieu F, Trouillon T, Bouchard G, Francois O. Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. Genetics 2014, 196: 973-983.
41. Li JF, Norville JE, Aach J, McCormack M, Zhang D, Bush J, Church GM, et al. Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat Biotechnol 2013, 31: 688-691.
42. JiangW, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013, 31: 233-239.
43. Oh J-H, van Pijkeren J-P. CRISPR-Cas9-assisted recombineering in Lactobacillus reuteri. Nucleic Acids Res 2014, 42: e131.
44. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res 2013, 41: 4336-4343.
45. Yu J, Chen B, Duan C, Yang S. Multigene editing in the Escherichia coli genome using the CRISPR-Cas9 system. Appl Environ Microbiol 2015. doi: 10.1128/AEM04023-14.
46. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337: 816-821.
47. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. Practical Streptomyces genetics. Norwich: John Innes Foundation. 2000.
48. Lu Z, Xie P, Qin Z. Promotion of markerless deletion of the actinorhodin biosynthetic gene cluster in Streptomyces coelicolor(dagger). Acta Biochim Biophys Sin 2010, 42: 717-721.
49. Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc 2013, 8: 2180-2196.
50. Fink D, Weissschuh N, Reuther J, Wohlleben W, Engels A. Two transcriptional regulators GlnR and GlnRII are involved in regulation of nitrogen metabolism in Streptomyces coelicolor A3(2). Mol Microbiol 2002, 46: 331-347.
51. Tiffert Y, Supra P, Wurm R, WohllebenW, Wagner R, Reuther J. The Streptomyces coelicolor GlnR regulon: identification of new GlnR targets and evidence for a central role of GlnR in nitrogen metabolism in actinomycetes. Mol Microbiol 2008, 67: 861-880.
52. Shima J, Hesketh A, Okamoto S, Kawamoto S, Ochi K. Induction of actinorhodin production by rpsL (encoding ribosomal protein S12) mutations that confer streptomycin resistance in Streptomyces lividans and Streptomyces coelicolor A3(2). J Bacteriol 1996, 178: 7276-7284.
53. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339: 819-823.
54. Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci Rep 2014, 4: doi: 10.1038/srep05400.
55. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013, 31: 822-826.
56. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. Highthroughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013, 31: 839-843.
57. Burgess DJ. Technology: characterizing CRISPR off-target effects. Nat Rev Genet 2014, 15: 5.
58. Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N, Wile BM, et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res 2014, 42: 7473-7485.
59. Zhu LJ, Holmes BR, Aronin N, Brodsky MH. CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genomeediting systems. PLoS One 2014, 9: e108424.
60. Cobb RE, Wang Y, Zhao H. High-efficiency multiplex genome editing of streptomyces species using an engineered CRISPR/Cas system. ACS Synth Biol 2014, doi: 10.1021/sb500351f.